Article
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?
Leukemia - 1 Jul 2026
Montoro Maria Julia, Acha Pamela, Haferlach Claudia, Chan Onyee, Navarro Víctor, Kubota Yasuo, Schulz Felicitas, Briski Robert, Al Ali Najla H, Xicoy Blanca, Palomo Laura, López-Cadenas Felix, Bosch Francesc, Meggendorfer Manja, González Teresa, Eder Lea Naomi, Jerez Andrés, Wang YuHung, Campagna Alessia, Betz Beate, Santini Valeria, Bernal Teresa, Such Esperanza, Platzbecker Anne Sophie, Kewan Tariq, Gurnari Carmelo, Zindel Carla, Kulasekararaj Austin, Voso Maria Teresa, Sekeres Mikkael, Díaz-Varela Nicolas, Al-Kali Aref, Polini Antonella, Diral Elisa, Memoli Mara, Platzbecker Uwe, Haase Detlef, Zeidan Amer M, Díez-Campelo María, Garcia-Manero Guillermo, Wiseman Daniel H, Della Porta Matteo G, Germing Ulrich, Maciejewski Jaroslaw, Komrokji Rami S, Solé Francesc, Haferlach Torsten, Fenaux Pierre, Valcárcel David
Abstract excerpt
Myelodysplastic neoplasms (MDS) with TP53 multihit alterations are associated with dismal outcomes. MDS with isolated del(5q) present favorable prognosis but is defined by the absence of TP53 multihit alterations. However, whether TP53 multihit alterations exert the same adverse impact in this genetic context remains uncertain. We retrospectively analyzed the characteristics and outcome of 43 patients with MDS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.